MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
1.330
-0.060
-4.32%
Closed 19:59 11/16 EST
OPEN
1.415
PREV CLOSE
1.390
HIGH
1.468
LOW
1.265
VOLUME
1.33M
TURNOVER
907.27K
52 WEEK HIGH
3.430
52 WEEK LOW
0.4100
MARKET CAP
87.46M
P/E (TTM)
-2.6815
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HURA last week (1109-1113)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: TuHURA Biosciences (HURA), Kiora Pharmaceuticals (KPRX)
TipRanks · 2d ago
TuHURA Biosciences reports Q3 results
Seeking Alpha · 3d ago
TuHURA Biosciences reports Q3 EPS (10c) vs. (14c) last year
TipRanks · 4d ago
Weekly Report: what happened at HURA last week (1102-1106)?
Weekly Report · 11/09 10:20
TuHURA Biosciences Borrows Additional Funds Under Credit Facility
TipRanks · 11/06 22:35
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
PR Newswire · 11/04 14:15
Weekly Report: what happened at HURA last week (1026-1030)?
Weekly Report · 11/02 10:20
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.